KLRA — Kailera Therapeutics, Inc. stock price, charts and financials

Latest market price

18.11

+0.79+4.56%

Overview Short InterestFilings

KLRAQT13Kailera Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

18.11+4.56%

Loading chart...

Screen all →

AMLX+8.43%$21.87 BCRX+2.38%$9.02 PHVS+5.02%$33.87 SION+1.38%$49.94 MLYS+2.79%$26.50 IMNM+8.91%$25.06 VERA-7.07%$29.95 ANAB+2.74%$55.13

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	129.57M	Perf Week	-0.92%

Market Cap	2.24B	Forward P/E	-	EPS next Y	-3.84	Insider Trans	17.15%	Shs Float	89.33M	Perf Month	-21.24%

Enterprise Value	1.71B	PEG	-	EPS next Q	-0.76	Inst Own	-	Short Float	7.18%	Perf Quarter	-31.13%

Income	-149.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	6.89	Perf Half Y	-

Sales	0.00	P/B	-	EPS next Y	-6.56%	ROA	-21.52%	Short Interest	6.41M	Perf YTD	-33.38%

Book/sh	-2.75	P/C	4.11	EPS next 5Y	-	ROE	41.79%	52W High	29.52 -38.65%	Perf Year	-

Cash/sh	4.21	P/FCF	-	EPS past 3/5Y	-	ROIC	-24.48%	52W Low	17.14 5.67%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.99% 7.34%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-	Oper. Margin	0.00%	ATR (14)	1.37	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	12.01	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	39.19	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	12.01	EPS Q/Q	-	SMA20	-6.99%	Beta	1.23	Target Price	42.00

Payout	0.00%	Debt/Eq	-	Sales Q/Q	-	SMA50	-13.71%	Rel Volume	0.52	Prev Close	17.32

Employees	145	LT Debt/Eq	-0.03	Earnings	Aug 25	SMA200	-17.82%	Avg Volume	691.67K	Price	18.11

IPO Date	Apr 17, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-470867.74% -	Net Debt/EBITDA	0.95	Volume	357,491	Change	4.56%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-12-26	Initiated	Leerink	Outperform	$36
May-12-26	Initiated	Jefferies	Buy	$48

Latest News

Jul-15-26

Jul-15-2601:00AM

2 Beaten-Down GLP-1 Stocks to Buy on the Dipfool.com

Jul-09-26

Jul-09-2605:00AM

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To WinSeekingAlpha

Jul-07-26

Jul-07-2612:45PM

Why Is Kailera Therapeutics Stock Falling Tuesday?benzinga.com

07:09AM

Kailera's GLP-1 drug meets main goal of late-stage trialsreuters.com

07:05AM

Kailera Therapeutics Announces Topline Data From Two Additional Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535 Conducted By Hengrui Pharma In ChinaBenzinga

Company

Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)		FY 2025 12/31/2025
Total Revenue		0
Cost of Goods Sold Incl. D&A		0
Gross Profit		0
Selling, General and Administrative Excl. Other		49
Research and Development		109
Other Operating Expense		0
Operating Income		-158
Interest Expense		0
Unusual Expense		—
Non-Operating Income (Expense)		9
Net Income Before Taxes		-149
Income Taxes		0
Consolidated Net Income		-149
Net Income From Continuing Operations		-149
Net Income		-149
EPS (Recurring)		-1.26
EPS (Basic, Before Extraordinaries)		-1.26
EPS (Diluted)		-1.26
EBITDA		-158
Other After Tax Adjustments		—
Stock Option Compensation Expense		—
Price To Earnings Ratio		—
Price To Sales Ratio		—
Gross Margin		—
Operating Margin		—
Net Margin		—
Shares Outstanding		118
Market Capitalization		—
Operating Lease Expense		—

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Renaud Ronald C JR	CEO & President	Jun 09 '26	Option Exercise	5.25	38,094	199,994	38,094	Jun 11
RTW INVESTMENTS, LP	10% Owner	Apr 20 '26	Buy	16.00	500,000	8,000,000	10,776,820	Apr 22
Bain Capital Life Sciences Investors, LLC	10% Owner	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20
BAIN CAPITAL INVESTORS LLC	10% Owner	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20
Koppel Adam	director, 10 percent owner:	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20
Kaplan Andrew T.	director, 10 percent owner:	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.